William Blair Investment Management LLC Sells 720,477 Shares of Twist Bioscience Corporation $TWST

William Blair Investment Management LLC cut its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 33.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,454,117 shares of the company’s stock after selling 720,477 shares during the period. Twist Bioscience comprises approximately 0.9% of William Blair Investment Management LLC’s holdings, making the stock its 13th largest holding. William Blair Investment Management LLC’s holdings in Twist Bioscience were worth $280,994,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Private Advisory Group LLC bought a new position in shares of Twist Bioscience in the 3rd quarter valued at about $1,533,000. Russell Investments Group Ltd. raised its holdings in Twist Bioscience by 190.8% during the third quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company’s stock worth $54,863,000 after acquiring an additional 186,294 shares in the last quarter. Pier 88 Investment Partners LLC bought a new stake in Twist Bioscience during the third quarter worth about $676,000. Lisanti Capital Growth LLC acquired a new position in Twist Bioscience during the third quarter valued at approximately $5,584,000. Finally, Ritholtz Wealth Management acquired a new position in Twist Bioscience during the third quarter valued at approximately $327,000.

Analysts Set New Price Targets

A number of research analysts have weighed in on TWST shares. Guggenheim raised their price target on Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Leerink Partners cut their price objective on Twist Bioscience from $190.00 to $175.00 and set an “outperform” rating for the company in a report on Friday. Canaccord Genuity Group decreased their target price on shares of Twist Bioscience from $205.00 to $150.00 and set a “buy” rating for the company in a research note on Friday. Finally, Barclays boosted their target price on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Twist Bioscience has a consensus rating of “Hold” and a consensus target price of $141.00.

Get Our Latest Research Report on TWST

Twist Bioscience Stock Performance

Shares of NASDAQ TWST opened at $111.60 on Monday. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $7.00 billion, a P/E ratio of -53.40 and a beta of 2.25. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $219.71. The stock has a 50 day moving average of $150.23 and a 200-day moving average of $93.07.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. The company’s revenue for the quarter was up 26.7% on a year-over-year basis. As a group, equities research analysts predict that Twist Bioscience Corporation will post -1.52 EPS for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,797,004.32. Following the completion of the sale, the insider directly owned 63,789 shares in the company, valued at $12,048,466.32. This trade represents a 12.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily Leproust sold 356,546 shares of Twist Bioscience stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $157.99, for a total value of $56,330,702.54. Following the sale, the chief executive officer directly owned 620,589 shares of the company’s stock, valued at approximately $98,046,856.11. The trade was a 36.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 495,279 shares of company stock valued at $80,489,387 in the last ninety days. Company insiders own 3.08% of the company’s stock.

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Further Reading

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.